Date: 2014-05-29
Type of information: Financing round
Company: Epidarex Capital (UK)
Investors: Eli Lilly (USA) King’s College London (UK) European Investment Fund (EU) Scottish Enterprise (UK) Strathclyde Pension Fund (UK), University of Edinburgh (UK) University of Glasgow (UK) University of Aberdeen (UK)
Amount: £47.5 million (€58.3 million)
Funding type: financing round
Planned used: These funds will be used to lead investments in early-stage life science and health technology companies, including spin-outs from leading research universities.
Others: * On May 29, 2014, Epidarex Capital, a leading international venture capital firm, has announced it has raised over £47.5 million to lead investments in early-stage life science and health technology companies. Eli Lilly and participated in the final closing with a significant capital commitment. King’s College London also invested in the final closing. The fund’s early-stage focus is supported by a diverse range of investors, including four top research universities as well as the European Investment Fund, Scottish Enterprise and Strathclyde Pension Fund. Epidarex’s close working relationship with the Universities of Edinburgh, Glasgow and Aberdeen, as well as with King’s College London, provides access to some of the most innovative healthcare start-ups, including those specialising in novel drug development. Lilly’s investment, its first in a UK venture fund, signifies the strength of the early-stage life science sector across the UK and endorses Epidarex’s approach of deploying resources and capital into the commercialisation of the most innovative healthcare technologies at an early-stage.
Therapeutic area:
